Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibodies Against Infliximab Are Associated with De Novo Development of Antibodies to Adalimumab and Therapeutic Failure in Infliximab-to-Adalimumab Switchers with IBD
Authors
Keywords
-
Journal
INFLAMMATORY BOWEL DISEASES
Volume 20, Issue 10, Pages 1714-1721
Publisher
Oxford University Press (OUP)
Online
2014-07-26
DOI
10.1097/mib.0000000000000138
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
- (2013) R. Khanna et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- Comparison of Techniques for Monitoring Infliximab and Antibodies Against Infliximab in Crohnʼs Disease
- (2013) Casper Steenholdt et al. THERAPEUTIC DRUG MONITORING
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
- (2012) Pauline A van Schouwenburg et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
- (2012) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
- (2011) C. Steenholdt et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease
- (2011) L. S. Kiss et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial
- (2011) Gert Van Assche et al. GUT
- Guidelines for the management of inflammatory bowel disease in adults
- (2011) C. Mowat et al. GUT
- Long-term durability of response to adalimumab in Crohnʼs disease
- (2011) M. Chaparro et al. INFLAMMATORY BOWEL DISEASES
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee
- (2010) Asher Kornbluth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
- (2010) S. Ben-Horin et al. GUT
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Management of Crohn's Disease in Adults
- (2009) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study
- (2009) G. M. Bartelds et al. ANNALS OF THE RHEUMATIC DISEASES
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
- (2009) Klaus Bendtzen et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- European evidence-based Consensus on the management of ulcerative colitis: Current management
- (2008) S.P.L. Travis et al. Journal of Crohns & Colitis
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started